ERBB2 and breast cancer: A study has shown that CAR-T cells based on the extracellular domain of HRG1β, a natural ligand of HER3/HER4, can effectively inhibit HER family receptor–driven BC, which may provide a new strategy to overcome tumor resistance to HER2-targeted therapy [133].